Cover Image
市場調查報告書

鼻咽癌:開發中產品分析

Nasopharyngeal Cancer - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 229772
出版日期 內容資訊 英文 194 Pages
訂單完成後即時交付
價格
Back to Top
鼻咽癌:開發中產品分析 Nasopharyngeal Cancer - Pipeline Review, H2 2016
出版日期: 2016年08月31日 內容資訊: 英文 194 Pages
簡介

鼻咽癌是發生於頸部及頭部的罕見型癌症,常發生在喉嚨上部或鼻子內側。這部分被稱為鼻咽頭,鼻咽癌的危險因子是EB病毒。症狀有視線模糊或複視、包含嘶啞的發聲困難、不斷重複的耳道感染、臉部疼痛或是無知覺、頭痛、重聽、耳鳴等。治療方法有手術、化療及放射線療法等。

本報告提供鼻咽癌的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您加上最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。。

簡介

  • 調查範圍

鼻咽癌 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關研究中的產品

治療藥開發企業

  • Advenchen Laboratories, LLC
  • Ambrx, Inc.
  • arGEN-X BV
  • Atara Biotherapeutics, Inc.
  • AVEO Pharmaceuticals, Inc.
  • Betta Pharmaceuticals Co. Ltd.
  • BioDiem Ltd
  • Biomics Biotechnologies Co., Ltd.
  • Celgene Corporation
  • Cell Medica Limited
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline Plc
  • Lakewood-Amedex Inc
  • Merck & Co., Inc.
  • Merck KGaA
  • Molecular Partners AG
  • Novartis AG
  • 小野藥品工業
  • Pharmacyclics, Inc.
  • Sapvax
  • Tessa Therapeutics Pte Ltd
  • Theravectys SA

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8421IDB

Summary

Global Markets Direct's, 'Nasopharyngeal Cancer - Pipeline Review, H2 2016', provides an overview of the Nasopharyngeal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nasopharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nasopharyngeal Cancer and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nasopharyngeal Cancer
  • The report reviews pipeline therapeutics for Nasopharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Nasopharyngeal Cancer therapeutics and enlists all their major and minor projects
  • The report assesses Nasopharyngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Nasopharyngeal Cancer

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Nasopharyngeal Cancer
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nasopharyngeal Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nasopharyngeal Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Nasopharyngeal Cancer - Overview
    • Pipeline Products for Nasopharyngeal Cancer - Comparative Analysis
  • Nasopharyngeal Cancer - Therapeutics under Development by Companies
  • Nasopharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes
  • Nasopharyngeal Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Nasopharyngeal Cancer - Products under Development by Companies
  • Nasopharyngeal Cancer - Products under Investigation by Universities/Institutes
  • Nasopharyngeal Cancer - Companies Involved in Therapeutics Development
    • Advenchen Laboratories, LLC
    • Ambrx, Inc.
    • arGEN-X BV
    • Atara Biotherapeutics, Inc.
    • AVEO Pharmaceuticals, Inc.
    • Betta Pharmaceuticals Co. Ltd.
    • BioDiem Ltd
    • Biomics Biotechnologies Co., Ltd.
    • Celgene Corporation
    • Cell Medica Limited
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline Plc
    • Lakewood-Amedex Inc
    • Merck & Co., Inc.
    • Merck KGaA
    • Molecular Partners AG
    • Novartis AG
    • Ono Pharmaceutical Co., Ltd.
    • Pharmacyclics, Inc.
    • Sapvax
    • Tessa Therapeutics Pte Ltd
    • Theravectys SA
  • Nasopharyngeal Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abexinostat hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • apatinib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ARGX-110 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • atezolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • avelumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • azacitidine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • baltaleucel-T - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Nasopharyngeal Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Solid Tumor and Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target Latent Membrane Protein-2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • DC-120 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EBV-nRNA - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Epstein-Barr virus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ficlatuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSK-2849330 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • icotinib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JS-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • LAG-525 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit GAL-9 for Nasopharyngeal Carcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibody Drug Conjugate to Target CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MP-0250 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MVA vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NEO-212 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nimotuzumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • nivolumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PDR-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pembrolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-5203280 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Nasopharyngeal and Colon Cancers - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SV-638 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TT-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine to Target EBV for Nasopharyngeal Carcinoma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nasopharyngeal Cancer - Dormant Projects
  • Nasopharyngeal Cancer - Discontinued Products
  • Nasopharyngeal Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Jun 23, 2016: Atara Bio Receives Advanced Therapy Medicinal Product Classification for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes (EBV-CTLs) from European Medicines Agency (EMA)
      • Jun 06, 2016: Atara Bio Announces Clinical Trial Results for the Treatment of EBV+ Nasopharyngeal Carcinoma using Allogeneic Epstein-Barr Virus Cytotoxic T-Lymphocyte Product Candidate
      • May 18, 2016: Atara Bio Announces Presentation of Clinical Data from EBV-CT Product Candidate at the Upcoming 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
      • Apr 19, 2016: Atara Biotherapeutics Collaborator QIMR Berghofer Medical Research Institute Reports Positive Clinical Data for T Cell Immunotherapy in Nasopharyngeal Cancer (NPC), a Solid Tumor
      • Mar 16, 2016: Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the American Association for Cancer Research Annual Meeting
      • Sep 26, 2015: New Findings Show Anti-Tumor Activity of KEYTRUDA in Patients with Advanced Nasopharyngeal Carcinoma
      • Sep 10, 2015: U.S. FDA grants Fast Track Designation to Tessa Therapeutics' TT10 EB-VST for the treatment of Head and Neck Cancers
      • Mar 27, 2015: U.S. FDA approves Tessa Therapeutic's IND application to begin Phase III trial involving Adoptive T cell therapy on Nasopharyngeal Cancer
      • Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Nasopharyngeal Cancer, H2 2016
  • Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Nasopharyngeal Cancer - Pipeline by Advenchen Laboratories, LLC, H2 2016
  • Nasopharyngeal Cancer - Pipeline by Ambrx, Inc., H2 2016
  • Nasopharyngeal Cancer - Pipeline by arGEN-X BV, H2 2016
  • Nasopharyngeal Cancer - Pipeline by Atara Biotherapeutics, Inc., H2 2016
  • Nasopharyngeal Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H2 2016
  • Nasopharyngeal Cancer - Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016
  • Nasopharyngeal Cancer - Pipeline by BioDiem Ltd, H2 2016
  • Nasopharyngeal Cancer - Pipeline by Biomics Biotechnologies Co., Ltd., H2 2016
  • Nasopharyngeal Cancer - Pipeline by Celgene Corporation, H2 2016
  • Nasopharyngeal Cancer - Pipeline by Cell Medica Limited, H2 2016
  • Nasopharyngeal Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Nasopharyngeal Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Nasopharyngeal Cancer - Pipeline by Lakewood-Amedex Inc, H2 2016
  • Nasopharyngeal Cancer - Pipeline by Merck & Co., Inc., H2 2016
  • Nasopharyngeal Cancer - Pipeline by Merck KGaA, H2 2016
  • Nasopharyngeal Cancer - Pipeline by Molecular Partners AG, H2 2016
  • Nasopharyngeal Cancer - Pipeline by Novartis AG, H2 2016
  • Nasopharyngeal Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Nasopharyngeal Cancer - Pipeline by Pharmacyclics, Inc., H2 2016
  • Nasopharyngeal Cancer - Pipeline by Sapvax, H2 2016
  • Nasopharyngeal Cancer - Pipeline by Tessa Therapeutics Pte Ltd, H2 2016
  • Nasopharyngeal Cancer - Pipeline by Theravectys SA, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Nasopharyngeal Cancer - Dormant Projects, H2 2016
  • Nasopharyngeal Cancer - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Nasopharyngeal Cancer, H2 2016
  • Number of Products under Development for Nasopharyngeal Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top